A phase I/II study of chemotherapy followed by donor lymphocyte infusion plus interleukin-2 for relapsed acute leukemia after allogeneic hematopoietic cell transplantation.

[1]  Marcela R. Uribe,et al.  Donor KIR Genes 2DL5A, 2DS1 and 3DS1 are associated with a reduced rate of leukemia relapse after HLA-identical sibling stem cell transplantation for acute myeloid leukemia but not other hematologic malignancies. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[2]  J. Ritz,et al.  Feasibility, Safety, Efficacy And Immunologic Impact Of Daily Ultra-Low-Dose Interleukin-2 For Steroid-Refractory Chronic Graft-Versus-Host Disease: A Phase I Study , 2010 .

[3]  J. Rossi,et al.  Increased Plasma-Immune Cytokines throughout the High-Dose Melphalan-Induced Lymphodepletion in Patients with Multiple Myeloma: A Window for Adoptive Immunotherapy , 2009, The Journal of Immunology.

[4]  Mohamed A. Shaker,et al.  Interleukin-2: evaluation of routes of administration and current delivery systems in cancer therapy. , 2009, Journal of pharmaceutical sciences.

[5]  C. Yee,et al.  Fludarabine Modulates Immune Response and Extends In Vivo Survival of Adoptively Transferred CD8 T Cells in Patients with Metastatic Melanoma , 2009, PloS one.

[6]  J. Ritz,et al.  Combined CD4+ donor lymphocyte infusion and low-dose recombinant IL-2 expand FOXP3+ regulatory T cells following allogeneic hematopoietic stem cell transplantation. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[7]  D. Venzon,et al.  Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets , 2008, The Journal of experimental medicine.

[8]  M. Labopin,et al.  Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  R. Storb,et al.  Outcomes among patients with recurrent high-risk hematologic malignancies after allogeneic hematopoietic cell transplantation. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[10]  J. Wagner,et al.  Lymphodepletion followed by donor lymphocyte infusion (DLI) causes significantly more acute graft-versus-host disease than DLI alone. , 2006, Blood.

[11]  W. Telford,et al.  Dysregulation of IL-15-mediated T-cell homeostasis in TGF-beta dominant-negative receptor transgenic mice. , 2006, Blood.

[12]  S. Rosenberg,et al.  IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. , 2006, Blood.

[13]  J. Berzofsky,et al.  Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells , 2005, Nature Medicine.

[14]  C. Le,et al.  Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. , 2005, Blood.

[15]  N. Restifo,et al.  CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2. , 2005, Journal of immunotherapy.

[16]  T. Waldmann,et al.  IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T Cells , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[17]  J. Goldman,et al.  Adjuvant interleukin-2 therapy for patients refractory to donor lymphocyte infusions. , 2004, Experimental hematology.

[18]  F. Herrmann,et al.  Lymphokine activated killer cells , 1989, Blut.

[19]  Katia Perruccio,et al.  Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants , 2002, Science.

[20]  T. Braun,et al.  Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M. Labopin,et al.  Second allogeneic bone marrow transplantation in acute leukemia: results of a survey by the European Cooperative Group for Blood and Marrow Transplantation. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Steven A. Rosenberg,et al.  Progress in human tumour immunology and immunotherapy , 2001, Nature.

[23]  Robert H. Collins,et al.  Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  A. Nagler,et al.  Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. , 1996, Blood.

[25]  J. Thompson,et al.  Phase I trial of interleukin-2 after unmodified HLA-matched sibling bone marrow transplantation for children with acute leukemia. , 1996, Blood.

[26]  A Ferrant,et al.  Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. , 1995, Blood.

[27]  E D Thomas,et al.  1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.

[28]  R. Champlin,et al.  INTERLEUKIN‐2 FOR PREVENTION OF GRAFT‐VERSUS-HOST DISEASE AFTER HAPLOIDENTICAL MARROW TRANSPLANTATION , 1994, Transplantation.

[29]  J. Ritz,et al.  Effect of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation. , 1994, Blood.

[30]  T. Smetsers,et al.  Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  J. Radich,et al.  Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  J. Ritz,et al.  Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. , 1992, Blood.

[33]  J. Thompson,et al.  Toxicity and immunomodulatory effects of interleukin-2 after autologous bone marrow transplantation for hematologic malignancies. , 1991, Blood.

[34]  M. Caligiuri,et al.  Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors , 1990, The Journal of experimental medicine.

[35]  H. Heslop,et al.  Spontaneous and interleukin 2 induced secretion of tumour necrosis factor and gamma interferon following autologous marrow transplantation or chemotherapy , 1989, British journal of haematology.

[36]  R. Storb,et al.  Relapse of acute leukemia after marrow transplantation: natural history and results of subsequent therapy. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  J. Ortaldo,et al.  Lymphokine-activated killer cells. Analysis of progenitors and effectors , 1986, The Journal of experimental medicine.

[38]  F. Ruscetti.  Biology of interleukin-2 , 1984, Survey of immunologic research.

[39]  K. Sullivan,et al.  Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. , 1980, The American journal of medicine.